Jagsonpal Pharmaceuticals Ltd

Fri 9/10/2026,12:9:49 | NSE : JAGSNPHARM

₹227.68-4.02 (-1.74%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 228.64

Previous Close

₹ 231.70

Volume

19108

Mkt Cap ( ₹ Cr)

₹ 1501.72

High

₹ 232.40

Low

₹ 227.58

52 Week High

₹ 264.50

52 Week Low

₹ 155.00

Book Value Per Share

₹ 43.84

Dividend Yield

1.73

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Jagsonpal Pharmaceuticals Ltd

Your Vote -

Buy

77.78%

Hold

11.11%

Sell

11.11%

77.78%

9 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

51%

Sell Order Quantity

49%

Bid Price

Qty

227.60

6

228.00

11

228.00

1271

227.00

8

227.00

1

Bid Total

31724

Bid Price

Qty

227.97

2

228.00

1

228.00

4

228.00

1

228.00

2

Bid Total

30841

Option Chain

Analyzes market sentiment, predicts Jagsonpal Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Jagsonpal Pharma. - Updates

    1 Oct 2026, 5:00PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Subsequent to fulfilment of the Conditions Precedent under the BTA the transact

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    1 Oct 2026, 4:57PM Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026.

  • Jagsonpal Pharma. - Copy of Newspaper Publication

    30 Sep 2026, 4:14PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma. - Updates

    30 Sep 2026, 4:10PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited E

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Sep 2026, 4:09PM Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022

  • Jagsonpal Pharma. - Trading Window

    25 Sep 2026, 4:39PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Reg

  • Jagsonpal Pharma. - Press Release

    23 Sep 2026, 6:03PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 23, 2026, titled ""Press Release on Acquisition

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    23 Sep 2026, 6:03PM Press Release on Acquisition of Wellness Portfolio of Group pharmaceuticals Limited

  • Jagsonpal Pharma. - General Updates

    23 Sep 2026, 5:58PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about the Acquisition of Wellness Portfolio of Group Pharmaceuticals Limited.

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Acquisition

    23 Sep 2026, 5:53PM Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited.

  • Jagsonpal Pharma. - Shareholders meeting

    21 Sep 2026, 5:08PM Jagsonpal Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 18, 2026. Further,

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholders meeting

    18 Sep 2026, 5:21PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Shareholders meeting

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Outcome of AGM

    18 Sep 2026, 5:12PM Summary of Proceedings of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    21 Sep 2026, 5:05PM Voting Result and scrutinizer Report of 47th Annual General Meeting.

  • Jagsonpal Pharma. - Copy of Newspaper Publication

    28 Aug 2026, 12:14PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma. - Shareholders meeting

    27 Aug 2026, 8:22PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026

  • Jagsonpal Pharma. - Notice Of 47Th Annual General Meeting And Annual Report For The FY 2025-26

    27 Aug 2026, 8:18PM Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26

  • Jagsonpal Pharma. - Business Responsibility and Sustainability Reporting (BRSR)

    27 Aug 2026, 8:07PM BRSR for the Financial year ended March 31, 2026

  • Jagsonpal Pharma. - Reg. 34 (1) Annual Report.

    27 Aug 2026, 7:51PM Annual report for Financial Year 2025-26

  • Jagsonpal Pharma. - Updates

    27 Aug 2026, 5:41PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'providing a web-link of the Annual Report 2025-26 to members'.

  • Jagsonpal Pharma. - Announcement Under Regulation 30-SEBI (LODR) Regulations, 2015

    27 Aug 2026, 5:40PM Letter providing a web link of annual report 2025-26 to members.

  • Jagsonpal Pharma. - Updates

    24 Aug 2026, 11:56AM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Em

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    24 Aug 2026, 11:54AM Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022

  • Jagsonpal Pharma. has declared 200% Final dividend for the financial year March 2026

    19 Aug 2026, 3:10PM Jagsonpal Pharmaceuticals Ltd. on Monday, 27 April 2026, has announced Final dividend of 200 percent on Equity Share, to its shareholders holding shar

  • Jagsonpal Pharma. - Copy of Newspaper Publication

    12 Aug 2026, 5:01PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication on 47th Annual General Meeting (AGM) of the Company t

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Aug 2026, 4:23PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Transcript

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Aug 2026, 4:21PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Transcript

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    4 Aug 2026, 4:19PM Earning Call Transcript for meeting held on July 30, 2026

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Jul 2026, 5:30PM Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30, 2026 at 2:30 P.M.

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jul 2026, 5:30PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Link of Recording

  • Jagsonpal Pharma. - Copy of Newspaper Publication

    30 Jul 2026, 5:24PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma. - Change in Management

    29 Jul 2026, 6:49PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about change in Management

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    29 Jul 2026, 6:45PM Change in Senior Management personnel of the Company

  • Jagsonpal Pharma. - Corporate Action- Record Date: September 04, 2026

    29 Jul 2026, 6:37PM Corporate Action- Record Date for dividend Purpose: September 04, 2026

  • Jagsonpal Pharma. - General Updates

    29 Jul 2026, 6:34PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about 'Grant of 1,20,000 ESOP under JPL ESOP Plan 2022

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    29 Jul 2026, 6:32PM Intimation for grant of Employee Stock Options

  • Jagsonpal Pharma. - Press Release

    29 Jul 2026, 6:25PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 29, 2026, titled ""Press Release for Unaudited Financ

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    29 Jul 2026, 6:23PM Press Release for Unaudited Financial results for quarter ended June 30, 2026

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    29 Jul 2026, 6:21PM Press Release for Unaudited Financial Results for quarter ended June 30, 2026

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Jul 2026, 6:11PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation

  • Jagsonpal Pharma. - Record Date

    29 Jul 2026, 5:35PM Jagsonpal Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 04-Sep-2026.

  • Jagsonpal Pharma. - Outcome of Board Meeting

    29 Jul 2026, 5:10PM Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

  • Jagsonpal Pharma. - Unaudited Results For The Quarter Ended June 30, 2026

    29 Jul 2026, 5:20PM Unaudited results along with its Limited Review Report for the quarter ended June 30, 2026

  • Jagsonpal Pharma. - Board Meeting Outcome for Outcome Of Board Meeting Held On July 29, 2026 Along With Unaudited (Standalone

    29 Jul 2026, 5:01PM Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 2026

  • Jagsonpal Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Jul 2026, 4:25PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    22 Jul 2026, 4:23PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish t

  • Jagsonpal Pharma. - Board Meeting Intimation for Prior Intimation Of Board Meeting

    22 Jul 2026, 4:18PM Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to con

  • Jagsonpal Pharma. - Updates

    17 Jul 2026, 4:54PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Updates on Acquisition of Aequitas Healthcare Private Limited'.

  • Jagsonpal Pharma. - General-Updates

    17 Jul 2026, 4:52PM Updates on Acquisition of Aequitas Healthcare Private Limited.

  • Jagsonpal Pharma. - Updates

    15 Jul 2026, 4:34PM 'Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 94,000 Equity Shares under the Jagsonpal Pharmaceuticals Limited

  • Jagsonpal Pharma. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    15 Jul 2026, 4:39PM Allotment of 94,000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022.

  • Jagsonpal Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    13 Jul 2026, 6:40PM As of June 2026, 69.05% is owned by Promoters and 30.95% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 25.55% and Forei
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Jagsonpal Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 276.172 239.95 187.402 158.89 130.8556
Liabilities 276.172 239.95 187.402 158.89 130.8556
Equity 13.393 13.28 13.219 13.099 13.099
Gross Profit 58.074 51.071 23.067 34.151 25.7944
Net Profit 43.082 55.361 22.463 26.721 19.587
Cash From Operating Activities 46.812 55.3 35.166 46.655 5.5981
NPM(%) 14.99 20.6 10.76 11.28 8.66
Revenue 287.225 268.716 208.702 236.714 226.0967
Expenses 229.151 217.645 185.635 202.563 200.3023
ROE(%) 14.89 19.14 7.76 9.24 6.77

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
04 Sep 2026 4 200 1.76 203.67
12 Sep 2025 2.5 125 1.76 240.58
06 Sep 2024 5 100 1.76 351.15
21 Aug 2023 5 100 1.76 352.9
29 Oct 2021 4 80 1.76 162.15
22 Sep 2021 1 20 1.76 157.65
22 Sep 2020 0.5 10 1.76 35.15
20 Sep 2019 0.25 5 1.76 27.1
18 Sep 2018 0.1 2 1.76 26.7
21 Sep 2017 0.1 2 1.76 38.4
21 Sep 2016 0.1 2 1.76 33.85
21 Sep 2015 0.1 2 1.76 26.5
25 Sep 2014 0.5 10 1.76 23.65
25 Sep 2013 0.5 10 1.76 9.5
21 Sep 2012 0.5 10 1.76 12.35
23 Sep 2011 0.5 10 1.76 12.55
21 Sep 2010 0.5 10 1.76 23.85
23 Sep 2009 0.25 5 1.76 12.45
24 Sep 2008 0.1 2 1.76 13.4
21 Sep 2007 0.1 2 1.76 16.7
26 Sep 2006 0.1 2 1.76 19.25
26 Sep 2005 1 20 1.76 55.45
27 Aug 2004 0.5 10 1.76 244.25
30 May 2003 3.75 37.5 1.76 81.15
05 Mar 2002 0 20 1.76 111.85
11 Sep 2001 0 30 1.76 330
0 30 1.76 199

Peers

Other companies within the same industry or sector that are comparable to Jagsonpal Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 794.90 0.13 20.10 131.61 -26.19 0.63
Lotus Eye Hospital and Institute Ltd 114.43 0.43 1634.71 479.56 0.39 0.00
Vaishali Pharma Ltd 8.05 0.75 25.16 3008.45 15.42 0.00
Astec Lifesciences Ltd 728.25 1.89 0.00 513.83 -363.14 0.00

Company Info

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share.2024-The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd.-The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill. 2025-The Company has splits its face value from Rs. 5/- to Rs. 2/-.-The Company has acquire india business of Resilient Cosme-Ceuticals Private Limited along with the brands associated trademarks.

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share.2024-The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd.-The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill. 2025-The Company has splits its face value from Rs. 5/- to Rs. 2/-.-The Company has acquire india business of Resilient Cosme-Ceuticals Private Limited along with the brands associated trademarks.

Parent Organisation

Jagsonpal Pharmaceuticals Ltd.

Founded

17/08/1978

Managing Director

Mr.Manish Gupta

NSE Symbol

JAGSNPHARMEQ

FAQ